ViewRay launches pancreatic cancer trial for MRI-guided radiation therapy system

ViewRay (NSDQ:VRAY) announced today the launch of a prospective clinical trial evaluating its MRI-guided radiation therapy system, MRIdian, in patients with locally-advanced, unresectable pancreatic cancer.

The study was designed by ViewRay’s Clinical Cooperative Think Tank – a group of MRIdian users focused on gathering evidence to support MR-guided radiation therapy.

Early results presented at ASTRO helped to motivate the trial, the company reported. A review of 42 locally-advanced pancreatic cancer patients found that stereotatic dosing regimens guided by MR imaging and daily online adaptation led to prolonged patient survival and favorably low toxicity.

“Based on compelling early evidence on the use of MRIdian to treat locally advanced pancreatic cancer, we are eager to further explore the system’s capabilities and associated toxicity, local control and patient outcomes,” lead investigator Dr. Parag Parikh said in prepared remarks.

“We believe MRIdian’s excellent real-time visualization of organs at risk within the abdomen and its daily treatment adaptation will allow us to deliver higher, more effective doses to the target while minimizing impact on the normal surrounding tissue. The findings of this study could truly change the standard of care for many pancreatic cancer patients.”